China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three prior lines of treatment. The trial will include about 150 patients in China with relapsed of refractory multiple myeloma, and randomly assign them to the triple combination or to standard treatment with Velcade plus dexamethasone, and serving as a control group. Findings from a global…
You must be logged in to read/download the full post.
The post Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China appeared first on BioNewsFeeds.